The biotech licensing whizzes at Aditum Bio, the VC firm from ex-Novartis CEO Joe Jimenez and Mark Fishman, have created their 10th company by nabbing the rights to a preclinical autoimmune drug.
The new startup, Celexor Bio, will pay an undisclosed upfront and up to $287 million in biobucks to…
Click here to view original post
